1241 A robust, cost-effective technique based on whole-exome sequencing data can be used to characterize immune infiltrates, relate the extent of these infiltrates to somatic changes in tumours, and enables prediction of tumour responses to immune checkpoint inhibition therapy.
https://www.nature.com/articles/s41586-021-03894-5
1240 Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis.
https://www.nature.com/articles/s41586-021-03879-4
1239 The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.
https://www.science.org/doi/10.1126/science.abg5784
1238 Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.
https://www.science.org/doi/10.1126/scitranslmed.abc8188
1237 A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
https://www.science.org/doi/10.1126/scitranslmed.aba7791
1236 Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
https://www.cell.com/cell/fulltext/S0092-8674(21)00879-5
1235 METTL14 facilitates global genome repair and suppresses skin tumorigenesis.
https://www.pnas.org/content/118/35/e2025948118
1234 Cycling cancer persister cells arise from lineages with distinct programs.
https://www.nature.com/articles/s41586-021-03796-6
1233 A new computational approach to in silico mutagenesis screening allow comprehensive mapping of cancer driver mutations.
https://www.nature.com/articles/s41586-021-03771-1
1232 Drivers and suppressors of triple-negative breast cancer.
https://www.pnas.org/content/118/33/e2104162118
1231 Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.
https://stm.sciencemag.org/content/13/606/eabd1616
1230 UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth.
https://www.pnas.org/content/118/31/e2103592118
1229 EGFR activation limits the response of liver cancer to lenvatinib.
https://www.nature.com/articles/s41586-021-03741-7
1228 A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice.
https://stm.sciencemag.org/content/13/603/eabf1383
1227 Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.
https://www.pnas.org/content/118/29/e2023868118
1226 Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer.
https://stm.sciencemag.org/content/13/602/eaba4627
1225 Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
https://stm.sciencemag.org/content/13/602/eabb3631
1224 Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment.
https://www.pnas.org/content/118/28/e2101169118
1223 A nanovaccine based on bacterial cytoplasmic membranes and cell membranes from resected tumor tissue prevents tumor recurrence in mice.
https://stm.sciencemag.org/content/13/601/eabc2816
1222 Down-regulation of A20 promotes immune escape of lung adenocarcinomas.
https://stm.sciencemag.org/content/13/601/eabc3911
|
